Thomas E. Keane, MD, presented “Experience with Radical Perineal Prostatectomy at a Single Institution in the Era of Robotic-Assisted Laparoscopic Prostatectomy” during the 33rd International Prostate Cancer Update on January 24, 2023, in Vail, Colorado.
How to cite: Keane, Thomas E. “Experience with Radical Perineal Prostatectomy at a Single Institution in the Era of Robotic-Assisted Laparoscopic Prostatectomy.” January 2023, 2023. Accessed Jul 2024. https://grandroundsinurology.com/experience-with-radical-perineal-prostatectomy-at-a-single-institution-in-the-era-of-robotic-assisted-laparoscopic-prostatectomy/
Experience with Radical Perineal Prostatectomy at a Single Institution in the Era of Robotic-Assisted Laparoscopic Prostatectomy – Summary
Thomas E. Keane, MD, presents data on the use and outcomes of Radical Perineal Prostatectomy (RPP) as a treatment for prostate cancer. He begins by reviewing the many options available to patients, allowing their treatment to be customized by their disease, priorities, and functional status. He then focuses on the viability of RPP as a treatment option for a wider population, especially for those who do not qualify for robotic-assisted surgery.
In this presentation, Dr. Keane illustrates:
- The equipment necessary to perform RPP
- The steps of the surgery, with photographs at each stage
- The objectives of the surgery
- The results from patients who received RPP over the past ten years
Dr. Keane concludes by comparing the outcomes of patients treated with Robotic-Assisted Laparoscopic Prostatectomy (RALP) to those of RPP patients. After ten years, patients treated with RPP showed no difference in progression to metastatic disease, no difference in rates of urinary symptoms, and higher rates of continence when compared to those treated with RALP.
About The 33rd Annual International Prostate Cancer Update:
The International Prostate Cancer Update (IPCU), founded in 1990, is a multi-day CME conference focused on prostate cancer treatment updates with expert, international faculty. It is led by expert physicians and is designed for urologists, medical oncologists, radiation oncologists, and other healthcare professionals involved in the diagnosis and treatment of prostate cancer. The 33rd iteration of the meeting occurred January 22-25, 2023 in Vail, Colorado. To view more educational presentations from IPCU 33, visit our collection page.
ABOUT THE AUTHOR
Thomas E. Keane, MD, is Professor and Chairman of the Department of Urology at the Medical University of South Carolina in Charleston. Dr. Keane specializes in managing prostate, bladder, and renal cancers.
An avid researcher, Dr. Keane has served as principal investigator or co-investigator on more than 20 major clinical and preclinical studies. Much of his work focuses on innovative concepts in translational research, including utilizing human tumor xenografts to investigate the efficacy of new therapies as they relate to GU malignancies with particular reference to cytotoxic agents, sphingolipids, and boron-containing compounds. He holds a United States patent for sphingolipid derivatives and their use.
Dr. Keane’s research has led to publication of more than 100 articles peer-reviewed in such journals as The Journal of Urology, Urologic Oncology, and the Journal of Vascular Surgery. He provides editorial services to publications ranging from Urology to the International Journal of Cancer and is co-editor of the text Glenn’s Urologic Surgery, 6th, 7th, and 8th Editions. He is an accomplished speaker, having delivered many presentations to professional societies and symposia throughout the United States and abroad.
